Skip to main content
Nicholas Vogelzang, MD, Oncology, Las Vegas, NV

NicholasJVogelzangMD

Oncology • Las Vegas, NV

Chair and Medical Director of the Developmental Therapeutics Committee, Co-Chair of the Genitourinary Committee for U.S. Oncology Research, Medical Oncologist Medical Oncologist Comprehensive Cancer Centers of Nevada

Join to view full profile

Dr. Vogelzang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vogelzang's full profile

Already have an account?

  • Office

    3730 S Eastern Ave
    Las Vegas, NV 89169
    Phone+1 702-952-3400
    Fax+1 702-952-3461

Education & Training

  • University of Minnesota
    University of MinnesotaFellowship, Hematology and Medical Oncology, 1978 - 1980
  • Rush University Medical Center
    Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
  • Rush University Medical Center
    Rush University Medical CenterResidency, Internal Medicine, 1974 - 1977
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1974

Certifications & Licensure

  • NV State Medical License
    NV State Medical License 2004 - 2023
  • IL State Medical License
    IL State Medical License 1975 - 2011
  • MN State Medical License
    MN State Medical License 1978 - 1982
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Vegas Seven Castle Connolly, 2014
  • America's Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2009, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma  
    Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Lectures

  • Safety and clinical outcomes of GT0918 (Proxalutamide), a potent androgen receptor (AR) blocker, in patients with mCRPC progressing on standard (SoC) and experimental ... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

  • Transplant Recipient Offers Encouraging Message to Those Waiting: Don’t Give Up
    Transplant Recipient Offers Encouraging Message to Those Waiting: Don’t Give UpDecember 30th, 2022
  • Nicholas J. Vogelzang, MD, Posthumously Receives Humanitarian Award Named in His Honor
    Nicholas J. Vogelzang, MD, Posthumously Receives Humanitarian Award Named in His HonorNovember 7th, 2022
  • The Will to Live; Unhealthy Gut Bacteria; Promise of Genomic Testing Evolves
    The Will to Live; Unhealthy Gut Bacteria; Promise of Genomic Testing EvolvesSeptember 23rd, 2022
  • Join now to see all

Grant Support

  • Zoledronate In Osteoporosis Of Prostate CancerNational Center For Research Resources2004
  • Uccrc -Cancer Center Support GrantNational Cancer Institute2002–2003
  • Core--Developmental FundsNational Cancer Institute2002
  • Zoledronate &Osteoporotic Effects Of Androgen DeprivatiNational Center For Research Resources2000–2002
  • Pharmacokinetics Of ABT-627 In Subjects With Refractory MalignanciesNational Center For Research Resources2000–2002
  • Uccrc-Cancer Center Support GrantNational Cancer Institute2001
  • Uccrc--Cancer Center Support GrantNational Cancer Institute1999–2001
  • Prostate CancerNational Cancer Institute1996–2001
  • Phase I Study Of Cep-2563 Dihydrochloride In Adults With Solid TumorsNational Center For Research Resources1998–2000
  • Cancer And Leukemia Group BNational Cancer Institute1993–1998
  • Phase I Trial Of Ct-1501r And High Dose IL-2 In Renal Cancer Or MelanomaNational Center For Research Resources1995
  • Effect Of Food And Comparative Bioavailability Of Oral Bropirimine In CancerNational Center For Research Resources1994–1995
  • Phase I Trial Of Ct-1501r And High Dose IL 2 In Renal Cancer Or MelanomaNational Center For Research Resources1994
  • Cancer And LeukemiaNational Cancer Institute1989–1992
  • Cancer And Leukemia Group B Grant ApplicationNational Cancer Institute1988

Professional Memberships

Dr. Nicholas Vogelzang, Dr. Nicholas Vogelzang, MD, Dr. N Vogelzang, Dr. Nicholas J Vogelzang